Table 2.
Summarized data regarding eleven reviewed biomarkers (in descending order of the modified target selection criteria score).
| Biomarker | Therapeutic Antibody |
N | % Positive STS (Mean% + Range) | Pattern of Expression | Internalization | Previously Imaged | Score | Literature |
|---|---|---|---|---|---|---|---|---|
| Tumor endothelial marker 1 (TEM1/ endosialin/ CD248) | Ontuxizumab (MORAb-004) | 768 | 77% (55–100) | Diffuse | Yes, [25] | NIRF imaging [26] | 9 | [26,27,28,29] |
| Vascular endothelial growth factor receptor-1 (VEGFR-1) |
Aflibercept Bevacizumab | 477 | 76% (22–100) | Diffuse | Yes, [30] | NIRF imaging [30,31] | 8 | [32,33,34,35,36,37,38,39] |
| Epidermal growth factor receptor (EGFR) | Cetuximab | 1918 | 53% (0–100) | Diffuse | Yes, [40] | NIRF imaging [41] | 8 | [27,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76] |
| Vascular endothelial growth factor receptor-2 (VEGFR-2) |
Aflibercept Bevacizumab Ramucirumab |
449 | 71% (11–100) | Diffuse | Yes, [77] | NIRF imaging [78] | 7 | [33,34,35,36,38,39,79,80,81] |
| Insulin-like growth factor 1 receptor (IGF-1R) | Ganitumab (AMG 479) Teprotumumab Cixutumumab Figitumumab |
507 | 63% (25–100) | Diffuse | Yes, [82] | NIRF imaging [83] | 7 | [63,64,82,84,85,86,87,88,89] |
| Platelet derived growth factor receptor α (PDGFRα) | Olaratumab | 1536 | 64% (0–100) | Diffuse | Yes, [84] | NIRF imaging [85] | 7 | [27,34,36,38,42,43,44,45,46,47,48,49,51,82,86,87,88,89,90,91,92] |
| Cluster of differentiation 40 (CD40) | APX005M | 153 | 62% (17–86) | Diffuse | Yes, [93] | NIRF imaging [94] | 7 | [95,96,97,98] |
| Programmed death-ligand 1 (PD-L1/CD 274/B7-H1) | Atezolizumab Avelumab Durvalumab Envafolimab |
1492 | 31% (0–76) | Heterogeneous (focal and diffuse) | Yes, [99] | NIRF imaging [100] | 6 | [101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118] |
| Leucine-rich repeat containing 15 (LRRC15) | ABBV-085 | 635 | 40% | Diffuse | Not described | Not described | 4 | [102] |
| Receptor tyrosine kinase-like orphan receptor 2 (ROR2) | CAB-ROR2-ADC | 237 | 72% | Not described | Not described | Not described | 3 | [119] |
| Cytotoxic T-Lymphocyte-associated protein 4 (CTLA-4/CD152) | Ipilimumab Tremelimumab |
10 | 30% | Not described | Yes, [120] | Not with NIRF imaging [120] | 2 | [59] |
Note. Abbreviations: N, total number of samples; STS, soft tissue sarcoma; NIRF, near-infrared fluorescence